胸腺肽α1对糖尿病合并肺结核患者临床疗效的影响

发布时间：2018-04-05 04:14

本文选题：肺结核　切入点：糖尿病　出处：《中国老年学杂志》2015年15期

【摘要】：目的胸腺肽α1对糖尿病合并肺结核患者临床疗效的影响。方法 54例糖尿病合并肺结核患者随机分成对照组和观察组各27例。两组均予降血糖基础治疗和抗结核常规治疗,观察组在此基础上加用胸腺肽α1 1.6 mg,2次/w皮下注射。观察并比较两组的临床疗效及临床症状改善情况,同时检测治疗前后的外周血T淋巴细胞亚群(CD3+、CD4+、CD8+)和自然杀伤细胞(NK细胞)及血清中免疫球蛋白(Ig)A、Ig G和Ig M水平。结果观察组总有效率明显高于对照组(96.30%vs.81.48%,P0.05),痰菌转阴率明显高于对照组(77.78%vs.51.85%,P0.05),且空洞吸收、发热和咳嗽好转情况均优于对照组(P0.05);两组治疗前外周血中T淋巴细胞亚群、NK细胞比例和Ig A、Ig G、Ig M含量的差异均不显著(P0.05);与对照组比较,观察组治疗后CD3+、CD4+T淋巴细胞和NK细胞比例均增高,CD4+/CD8+比值增加(P0.05),且血清Ig G水平亦增高(P0.05)。两组治疗过程中均无严重不良反应且发生率的差异不显著(P0.05)。结论胸腺肽α1可提高糖尿病合并肺结核患者的临床疗效,可能与增强机体的免疫功能有关。
[Abstract]:Objective to study the effect of thymosin 伪 1 on diabetic patients with pulmonary tuberculosis.Methods 54 diabetic patients with pulmonary tuberculosis were randomly divided into control group (n = 27) and observation group (n = 27).Both groups were treated with basic hypoglycemic therapy and routine antituberculous therapy. In the observation group, thymosin 伪 11.6 mg / w was injected subcutaneously for 2 times.To observe and compare the clinical curative effect and clinical symptom improvement of the two groups. At the same time, the peripheral blood T lymphocyte subsets (CD3, CD 4, CD 4, CD 8) and natural killer cell (NK cell) and the levels of IgG G and IgM in serum were detected.Results the total effective rate of the observation group was significantly higher than that of the control group (96.30 vs 81.48), and the rate of sputum negative conversion was significantly higher than that of the control group (77.78 vs.51.85).The improvement of fever and cough was better than that of the control group (P 0.05), the percentage of NK cells in peripheral blood T lymphocyte subsets and the content of Ig G G G M in peripheral blood of the two groups were not significantly different from those in the control group.In the observation group, the ratio of CD4 / CD8 and serum Ig G were increased after treatment. The ratio of CD4 / CD8 and the level of serum IgG were also increased in the observation group.There were no serious adverse reactions and no significant difference in incidence between the two groups (P 0.05).Conclusion Thymosin 伪 1 can improve the clinical efficacy of diabetic patients with pulmonary tuberculosis, which may be related to the enhancement of immune function.
【作者单位】：武汉市医疗救治中心;
【基金】：武汉市卫生局科研课题(WX12C15)
【分类号】：R521;R587.1

【参考文献】